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Abstract
Tyrosine and phenolic ring de-iodination of thyroid hormones (TH) is crucial for regulating
their physiological activity. Furthermore, reactions such as de-carboxylation to thyrona-
mines (TAM) and de-amination to thyroacetic acids (TAc) produce TH metabolites (THM)
with distinct biological properties. This needs to be considered when studying effects of TH
and THM. The accurate and precise quantitative analysis of TH and THM in cell culture
supernatants and cell lysates are key procedures required for studying the in vitro metabo-
lism of TH. We report here the development of a liquid-liquid extraction/isotope dilution-liquid
chromatography-electrospray tandem mass spectrometry (LC-MS/MS) method for the
quantification of 9 thyronines (TN) and 6 TAM in human hepatocellular carcinoma Hep G2
cell lysate extracts. In addition, we adapted the method to quantify TH, TAM and TAc, in cell
lysates of FBS-depleted rat thyroid epithelium PCCL3 cells. The methods for both cell lines
were validated by rigorous assessment of linearity, limits of quantification and detection
(LLOQ and LLOD respectively), intra- and inter-day accuracy, precision, process efficiency
(PE), matrix effect (ME) and relative recovery (RE). Calibration curves covering 11 concen-
trations (based on 400 μl of lysate) were linear in the range 0.016–50 nM and 0.010–50 nM
for Hep G2 and PCCL3 cells respectively. The lower limits of quantification were in the
range 0.031 to 1 nM. We applied the PCCL3 version of the LC-MS/MS method to the analy-
sis of lysed cell extracts from PCCL3 cells that had been incubated with 3-iodo-L-thyronine
(T1), 3-iodothyronamine (3-T1AM) and 3-iodothyroacetic acid (3-T1Ac). Over the course of
30 minutes incubation 3-T1AM was de-iodinated to 4-[4-(2-aminoethylphenoxy)]phenol
(thyronamine, T0AM) and de-aminated to 3-T1Ac respectively, whilst T1 underwent de-iodin-
ation to T0. This data indicates avid metabolism of these mono-iodinated compounds and
the utility of LC-MS/MS to quantify such cellular metabolism.
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Introduction
The thyroid hormone (TH) 3,5,3’-triiodo-L-thyronine (T3) regulates a variety of processes that
ensure proper development, growth and metabolism. Most of the circulating T3 is generated
by de-iodination of the phenolic ring of the less active TH 3,5,3’,5’-tetraiodo-L-thyronine
(T4)–a reaction catalysed by deiodinases 1 and 2 in vivo [1, 2]. Inactivation of T4 is also accom-
plished by de-iodination, and leads to the formation of 3,3’,5’-triiodothyronine (reverse T3,
rT3); similarly, de-iodination of T3 generates either the active 3,5-diodothyronine (3,5-T2) or
the inactive 3,3’-diodothyronine 3,3’-T2), [3]. Besides de-iodination reactions, several other
pathways of TH metabolism are possible. TH metabolites (THM, see Fig 1.) include thyrona-
mines (TAM), resulting from TH de-carboxylation, and thyroacetic acids (TAc) resulting
from the deamination of TAM. Some of these THM are endogenous and possess biological
activity [4–7]. For example, 3,5-diiodothyronine (3, 5-T2) exerts thyromimetic action in
rodents [8, 9] and treatment with 3-iodothyronamine (3-T1AM) or 4-[4-(2-aminoethylphe-
noxy)]phenol (T0AM) produces partially TH antagonistic effects such as hypothermia in mice
and Djungarian hamsters [10, 11]. The mechanisms of action of TH and THM in cell culture
systems in vitro are of high scientific interest; however, uptake, release and intracellular metab-
olism affect their bioavailability or may lead to the formation of products with their own dis-
tinct biological activity in the experimental system. To elucidate how TH and THM are
utilised by cell types derived from different tissues can help clarify their mode(s) of action.
Hence, the development of a validated and convenient analytical method for TH, TAM and
TAc in cell extracts in vitro is of major importance.
We recently published a validated analytical method based on liquid-liquid extraction and
isotope dilution high performance liquid chromatography/tandem mass spectrometry (LC-
MS/MS) for the determination of 15 TH/THM (T0 to T4 thyronines (TN) and TAM, see Fig 1
for a complete list of compounds) in cell culture media extracts [12]. The method demon-
strated the accurate, reproducible quantification of THM within a single 10 min analysis, with
Fig 1. Molecular structures of TH, TAM and TAc.
https://doi.org/10.1371/journal.pone.0183482.g001
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lower limits of quantification (LLOQ) in the range 0.078–0.234 nM. We applied the method to
quantify the de-iodination metabolites 3,3’-T2, 3-T1 and T0 that were detected in DMEM
medium when T3 was incubated with primary hepatocytes [12]. We recently reported a pre-
liminary adaption of the above method to analyse a limited number of TN (T4, T3 and rT3) in
Madin-Darby canine kidney 1 cell lysate extracts as part of a study on molecular characteriza-
tion of monocarboxylate transporters involved in cellular TH uptake and efflux [13].
We now describe the extension of this method to enable the analysis and quantification of
TH, THM and TAc in extracted, lysed cells. The method has been validated for the 15 TH/
THM, using eight inter day replicates, for the human hepatocellular carcinoma cell line Hep
G2, applying US Federal Drug Administration guidelines [14]. In addition, the method was
validated (with 3-inter day repeats) for rat thyroid epithelium PCCL3 cells [15, 16] with the
inclusion of 3-iodothyroacetic acid (3-T1Ac) and thyroacetic acid (T0Ac). We applied the latter
method to the elucidation of potential metabolism pathways in cultured rat thyroid PCCL3
cells by incubating with 3-T1, 3-T1AM and 3-T1Ac.
Materials and methods
Chemicals, reagents, buffers, calibrators and quality control samples
The internal standards (IS) 13C6-T4,
13C6-T3,
13C6-rT3, and
13C6-3,3’-T2 were obtained from
Isosciences LLC (King of Prussia, PA, USA). Further IS, 2H4-3-T1AM,
2H4-3-T1Ac and
2H4-
T0Ac, were a generous gift from Dr. T.S. Scanlan (Portland, OR, USA).
T4AM, T3AM and rT3AM, were provided by Dr. R. Thoma (Formula GmbH, Berlin, D),
who also purified 3-T1AM by preparative HPLC. Dr. R. Smits (ABX Advanced Biochemical
Compounds, Radeberg, Germany) performed synthesis of high-purity 3-T1AM and T0AM.
3,5-T2AM, T1Ac and T0Ac were also kindly provided by T.S. Scanlan; T4, T3, 3,3
0-T2, 3,5-T2,
30,50-T2, 3-T1, 3
0-T1 and T0 were sourced from Henning Arzneimittel GmbH (Berlin, Ger-
many). 13C- and 1H-labelled internal standards contained no measurable concentrations of
unlabelled analogues and no cross-contamination from other 13C- or 1H-labelled TH. TN,
TAM and TAc were of minimum 99.6% purity. No corrections were made for potential cross-
contaminating compounds.
Certified reference standards of T3, 3,3’-T2 and T4 at 100 μg/mL in 0.1 N ammonium
hydroxide/methanol were purchased from Qmx Laboratories (Thaxted, UK).
CHROMASOLV1 Plus 2-Propanol, t-butyl methyl ether, methanol and dimethyl sulfoxide
(DMSO) were from Sigma-Aldrich Chemie GmbH (Munich, Germany) as was formic acid,
hydrochloric acid (37%), glacial acetic acid, sodium hydroxide and EDTA. Sucrose was pur-
chased from Carl Roth (Karlsruhe, Germany) and Hepes from Merck (Darmstadt, Germany).
Water was purified by a Milli-Q water purification system from Millipore (Billerica, MA,
USA) and was of 18.2 mO quality.
Coon’s F12 medium and fetal bovine serum (FBS) were purchased from Biochrom (Berlin,
Germany); bovine TSH, insulin, transferrin, hydrocortisone, glycyl-histidyl-lysine somato-
statin and DMEM (Dulbecco’s Modified Eagle’s medium) were obtained from Sigma Aldrich
(Munich, Germany).
Individual stock solutions of TN, TAM and TAc were prepared at 10 mM in DMSO. A
20 μM mixed TN/TAM (15 compounds) working solution of T4, T3, rT3, 3,30-T2, 3,5-T2,
30,50-T2, 3-T1, 3
0-T1, T0, T4AM, T3AM, rT3AM, 3,5-T2AM, 3-T1AM and T0AM was prepared
in 50% v/v methanol/water containing 0.1% formic acid (re-suspension buffer, RS). For
PCCL3 analyses an additional mixed TN/TAM/TAc (17 compounds) working solution, also at
20 μM, was prepared containing 3-T1Ac and T0Ac in addition to the above THM. A working
solution of certified reference standards containing a mixture of T4, T3 and 3,3
0-T2 at 20 μM
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was prepared in RS. Further working solutions at 1000, 100 and 10 nM were prepared in RS
and used to spike cell lysates to obtain calibrator and quality control samples. For Hep G2 cell
lysates in 24-well cell culture plates, calibrators were spiked at 0.016, 0.031, 0.063, 0.125, 0.25,
0.5, 1.25, 2.5, 5, 20 and 50 nM. In-house and external spiked quality-control samples (QQAL)
at low (LQAL, 0.10 nM), medium (MQAL, 12.5 nM) and high (HQAL, 40 nM) concentrations
were prepared by spiking cell lysates with either the appropriate in-house or certified reference
working standard solutions respectively. For PCCL3 cell lysates in 6-well cell culture plates,
calibrators were spiked at 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 12.5, 25, 50, 125, 250 and 500 nM. In-
house QQALs at low (LQAL, 0.10 nM), medium (MQAL, 1.0 nM) and high (HQAL, 2.5 nM)
concentrations were prepared by spiking cell lysates with in-house working standard solutions.





2H4-3-T1AM (all at 2 μM). For PCCL3 analyses an addi-
tional IS stock solution was prepared containing the same 5 stable-isotopically labelled stan-
dards plus 2H4-T0Ac and
2H4-T1Ac (also at 2 μM in DMSO). All stock solutions were stored at
-20˚C in brown glass vials with Teflon-lined screw tops.
Cell culture
All cell culture work was performed under standard culturing conditions (5% CO2 and 37˚C)
with standard aseptic techniques used throughout. Hep G2 medium was used without phenol
red indicator.
Hep G2 cells were cultured in DMEM culture medium supplemented with 10% FBS. Cells
were seeded in 24-well plates and grown confluent. At 24 h post plating, the medium was
changed. After a further 24 h the medium was again changed, but this time for culture media
without FBS. This state of cellular starvation was maintained for another 24 h, after which
plates destined for standard curve production were then taken to ice, the media aspirated and
the wells washed twice with ice cold PBS. The plates were stored dry at -20˚C.
Rat thyroid PCCL3 cells were cultured in Coon’s F12 medium supplemented with 5% FBS,
1 mU / ml bovine TSH and 5 hormones (10 μg / ml insulin, 5 μg / ml transferrin, 10 nM hydro-
cortisone, 20 ng / ml glycyl-histidyl-lysine and 10 ng / ml somatostatin). After seeding in
6-well plates at a density of 400,000 cells per well, the cells were grown for 24 h in medium as
described above. 24 h before experiments the cells were washed twice with PBS and grown in
medium without FBS to deplete them from TH and their metabolites. 24 h fasted PCCL3 cells
that were to be used to investigate TH metabolism were subjected to incubations with TH (or
just vehicle) in Krebs Ringer Buffer for various time points before being washed and stored in
the same manner as those destined for use in making standard curves.
Cell lysis and sample extraction
Homogenisation Buffer pH 7.4 (250 mM D-(+)Sucrose, 20 mM Hepes, 1 mM EDTA; HB) was
made and stored in aliquots at -20˚C for single use. HB was mixed 1:1 with 0.1 N NaOH to
produce Lysis Buffer 1 (LB1). Lysis Buffer 2 (LB2) consisted of 30% v/v glacial acetic acid in
HB. Both LB1 and LB2 were made freshly for each cell lysis.
The protocol stated was applied to both 6- (PCCL3) and 24- (Hep G2) well cell culture
plates. Cells were lysed at room temperature by adding 200 μl LB1 per well with orbital shaking
(600 rpm) for 3 min followed by the addition of 100 μl LB2. Calibrator and quality control des-
ignated wells were spiked with 95 μl of appropriate TN/TAM or TN/TAM/TAc working solu-
tion; those wells designated as unspiked or matrix controls received 95 μl RS. All wells except
those designated as matrix controls were then spiked with 5 μl of the appropriate IS mix.
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The resulting 400 μl cell lysates were transferred to 2.0 ml Eppendorf tubes and incubated
in the dark at 37˚C for 1 h. 1 ml of 30% v/v 2-propanol /t-butyl methyl ether was added to the
lysate and the mixture was vortexed for 5 min. The phases were separated via centrifugation at
2000 rcf for 5 min, at room temperature. The upper (non-aqueous) phase was transferred to a
new 2.0 ml Eppendorf tube, and the extraction process was repeated with a further 1 ml of
2-propanol /t-butyl methyl ether. The combined organic phases were dried to a pellet in an
Eppendorf 5301 Concentrator.
Samples, calibrators and quality controls were re-suspended in 100 μl of RS. Samples desig-
nated as matrix controls were re-suspended in 95 μl of TN/TAM or TN/TAM/TAc working
solution at the appropriate concentration, and then spiked with 5 μl of the appropriate IS Mix.
All samples were stored at -20˚C for LC-MS/MS analysis.
Incubation of PCCL3 cells with mono-iodinated TH, TAM and TAc
After 24 h under FBS depletion, PCCL3 cells were incubated +/- 500 nM 3-T1AM, 3-T1,
3-T1Ac or DMSO in Krebs Ringer buffer (119 mM NaCl, 4.74 mM KCl, 1.19 mM KH2PO4,
25 mM NaHCO3, 2.54 mM CaCl2, 1.19 mM MgCl2, 10mM Hepes, 11 mM glucose, pH 7.4,
1.5mL) for 5, 10 or 30 min. After removal of the incubation buffer, cells were washed 3 times
with PBS and frozen at -20˚C to await cell lysis and extraction as described in detail in the pre-
vious section. Supernatants were also stored at -20˚C; 400 μL aliquots were extracted as previ-
ously described [12]and analysed with the LC-MS/MS method described in the next section.
HPLC–MS/MS analysis
Sample analyses were performed by auto-injection of samples with a PAL HTC-xt auto-sam-
pler (CTC Analytics AG, Zwingen, Switzerland) onto an HSS PFP 2.5 μm 3.0x100 mm column
(Waters, Milford, MA, USA) maintained at 40˚C and served by a 1260 binary HPLC system
(Agilent technologies GmbH, Waldbronn, Germany). The HPLC column outlet was linked to
a Sciex API 6500 QTRAP mass spectrometer (SCIEX Germany GmbH, Darmstadt, Germany)
fitted with a Turbo Spray IonDrive electrospray source. The positive ion electrospray LC-MS/
MS method used for the analysis of TN, TAM and accompanying IS has been described in
detail [12] and was applied without modification to the analysis of extracted Hep G2 cell
lysates.
For the analysis of extracted PCCL3 cell lysates the electrospray method was extended to
facilitate positive/negative ion switching. The source temperature was reduced to 450˚C and
the ionspray voltage was -4500 V. The additional MRM transitions listed in Table 1 were
incorporated into the negative ion experiment. Dwell times of 10 ms were used throughout.
The complete duty cycle (positive plus negative ion) amounted to 0.73 sec.
Table 1. Negative ion electrospray tandem mass spectrometry and retention time (Rt) parameters for thyroacetic acids and internal standards.
Compound Rt (min) PI (m/z) Pro 1 (m/z) Pro 2 (m/z) DP (V) CE (V) CXP (V)
2H4-T0Ac 4.71 247.0 203.1 105.9 -15 -14 (-26) -9 (-5)
2H4-T1Ac 5.15 372.9 329.0 126.8 -5 -8 (-16) -15 (-13)
T0Ac 4.72 243.0 198.9 106 -10 -12 (-24) -9 (-5)
3-T1Ac 5.16 369.0 324.9 126.7 -15 -8 (-26) -13 (-19)
PI: precursor ion; Pro 1: quantifier product ion; Pro 2: confirmation product ion; DP: declustering potential; CE: collision energy; m/z: mass to charge ratio;
CXP: collision exit potential; V: volts. Values in parentheses refer to Pro 2.
https://doi.org/10.1371/journal.pone.0183482.t001
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For both Hep G2 and PCCL3 experiments the relative recoveries (RE), process efficiencies
(PE) and matrix effects (ME) were determined. The ME represents the impact of interfering
compounds (from the cell lysates and buffers) on analyte ionisation [17] and was calculated as
the percentage of [post extraction spiked MRM peak area]/[spiked solvent MRM peak area]
[18]. The PE, representing the amount of substance recovered after undergoing the extraction
process, is defined as the percentage of the [pre extraction spiked MRM peak area]/[post
extraction spiked MRM peak area]. A poor PE thus indicated the analyte(s) of interest were
lost during the extraction process [19]. The RE describes the percentage of the [pre extraction
spiked MRM peak area]/[spiked solvent MRM peak area]. Lower limits of quantification
(LLOQ) and detection (LLOD) were determined as described in reference [12] for calibrator
sample chromatographic peaks passing precision and accuracy tolerances20% and showing
signal:noise >10:1 and>6:1 respectively.
Results
Chromatographic peak measurement and identification
Representative chromatograms for TAM and TN in Hep G2 and for TAM, TN and TAc in
PCCL3 cell lysate extracts are displayed in Figs 2 and 3 respectively. For both Hep G2 and
Fig 2. T1AM, T0AM and T1Ac chromatograms from a PCCL3 cell lysate extract after 5 min incubation with T1AM. 2 MRM Traces per analyte,
overlayed. Upper trace: T1AM, middle trace: T0AM (4.56 min), lower trace: T1Ac.
https://doi.org/10.1371/journal.pone.0183482.g002
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PCCL3 methods the lowest chromatographic peak width was 12 sec. (obtained for 3,3’-T2); the
MS duty cycle allowed for a minimum of 15 data points to describe each peak to ensure repro-
ducible peak integration. For each analyte and internal standard two MRM transitions were
monitored; in most cases (except for 3-T1AM where background peaks interfered at the LLOQ)
the most intense peak was used as quantification ion and the less intense peak as confirmation
ion. To confirm the identity of metabolites arising from the incubation of PCCL3 cells with TH,
the observed quantification ion/confirmation ion MRM peak area ratios (MRMqc) were com-
pared with expected values (calculated from a standard solution of TN/TAM/TAc in RS) apply-
ing a ± 20% tolerance.
Fig 3. Thyronamine and thyronine chromatograms from Hep G2 cell lysate extracts spiked at 50 nM. 2
MRM Traces per analyte, overlayed. Upper trace: T0 (4.12 min); 3-T1 (4.54 min); 3-T1‘ (4.80 min); 3,5-T2 (4.60
min); 3,3‘-T2 (5.16 min); 3‘,5‘-T2 (5.35 min); T3 (5.01 min); rT3 (5.64 min); T4 (5.36 min). Lower trace: T0AM
(4.65 min); T1AM (5.30 min); 3,5-T2AM (5.34 min); T3AM (5.97 min); rT3AM (7.10 min); T4AM (inset, 6.56
min).
https://doi.org/10.1371/journal.pone.0183482.g003
LCMSMS method for PCCL3 thyrocytes
PLOS ONE | https://doi.org/10.1371/journal.pone.0183482 August 24, 2017 7 / 19
Excellent linearity for most THM in both cell lines and acceptable LLOD/
LLOQ
1/x Weighted linear regression calibration curves for each analyte were obtained by plotting
MRM peak area ratios (analyte/IS) against concentration over the working range 0.016–50 nM
for Hep G2 cell lysate extracts (except for T0: 0.50–50 nM) and 0.01–125 nM for PCCL3 cell
lysate extracts. 1/x weighted linear correlation coefficients (r2) for all compounds are displayed
in Table 2, and excellent linearity across the dynamic range of both methods for all analytes is
evidenced by a minimum value for r2 of 0.994.
The LLOD were in the range of 0.016–0.125 nM for Hep G2 cell lysate extracts in 24-well
format and 0.01–0.6 nM for PCCL3 cell lysate extracts in 6-well format. The LLOQ ranged
from 0.031–0.250 nM for Hep G2 and 0.04–1.0 nM for PCCL3. LLOD and LLOQ could not be
determined for T0 in Hep G2 cell lysate extracts, due to a background concentration of ca. 0.06
nM. Similarly, LLOD could not be calculated for T3 and T4 in PCCL3 cell lysate extracts
because of ca. 0.01 nM background concentration for both TN.
Reasonable accuracy and precision for spiked quality-control samples
(QQAL) in both cell lines
For Hep G2 inter- and intra-batch precision and accuracy were determined at low (LQAL),
medium (MQAL) and high (HQAL) concentrations of TN and TAM. Certified reference solu-
tions of three TN (3,3’-T2, T3 and T4) were purchased from a commercial supplier, diluted
accordingly and used alongside in-house prepared solutions for independent comparison.
8-Day inter-batch CVs for in-house QQALs (Table 3) were all< 13.5% across the entire
Table 2. Linearity and lower limits of detection and quantification for TH and TAM spiked lysed Hep G2 and PCCL3 cell extracts in 24- and 6-well
plates respectively.
Hep G2 PCCL3
Compound R2 Range LLOQ [nM] LLOD [nM] R2 Range LLOQ [nM] LLOD [nM]
T0 0.995–0.999 * * 0.996–1.000 0.050 0.025
3-T1 0.996–1.000 0.063 0.031 0.997–1.000 0.050 0.025
3’-T1 0.995–1.000 0.031 0.016 0.997–1.000 0.050 0.025
3,5-T2 0.996–1.000 0.125 0.063 0.996–1.000 0.050 0.025
3,3’-T2 0.996–1.000 0.063 0.031 0.998–0.999 0.100 0.025
3’,5’-T2 0.995–0.999 0.031 0.016 0.997–1.000 0.050 0.025
T3 0.995–1.000 0.063 0.016 0.997–0.999 0.040 **
rT3 0.997–1.000 0.063 0.031 0.998–0.999 0.100 0.010
T4 0.996–1.000 0.063 0.016 0.997–0.999 0.040 **
T0AM 0.995–1.000 0.125 0.063 0.996–0.999 0.500 0.025
3-T1AM 0.996–1.000 0.031 0.016 0.997–0.999 0.100 0.020
3,5-T2AM 0.996–1.000 0.063 0.031 0.998–1.000 0.050 0.025
T3AM 0.994–1.000 0.063 0.031 0.997–0.999 0.050 0.010
rT3AM 0.995–0.999 0.063 0.031 0.997–0.999 0.050 0.010
T4AM 0.996–0.998 0.250 0.125 0.995–0.999 0.500 0.100
T0Ac - - - 0.995–0.999 1.000 0.330
3-T1Ac - - - 0.996–0.999 1.000 0.600
R2: Pearson coefficient, 1/x weighted linear regression. LLOQ: lower limit of quantification LLOD: lower limit of detection.
*LLOD/LLOQ not quantifiable (lysed cell extracts contained ca. 0.10 nM T0)
** LLOD not quantifiable (lysed cell extracts contained ca. 0.010nM T4 and T3)
https://doi.org/10.1371/journal.pone.0183482.t002
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concentration range, with the exception of T0 (not quantifiable for LQAL, otherwise < 5.7%),
3,5-T2, T0AM and T4AM (LLOQ < LQAL, otherwise < 12.5%) and< 8.7% for certified refer-
ence QQALs (with the exception of LQAL for 3,3’-T2 and T3 which were< 17.8%). Intra-
batch CVs were< 15.0% (in-house solutions only, Table 4). 8-Day inter-batch accuracy for in
house QQALs were between 92.5–109.4% and for certified reference QQALs between 94.0–
114.5% (Table 3). Intra-batch accuracies were determined for in-house solutions only and
exhibited values in the range 92.0–120.0% (Table 4).
For PCCL3 inter-batch precision and accuracy were determined for QQALs using in-house
prepared spike-solutions at 3 concentrations spanning the appropriate range for the occurrence
of THM investigated in the accompanying application (0.10, 1.0 and 2.5 nM). 3-Day inter-batch
CVs were all< 10.5% with the exception of the T2, T3 and T4 TAM (< 23.1% for LQAL,<
14.2% for MQAL and< 16.4% for HQAL) (Table 5). Intra-batch CVs (Table 6), measured at
0.10 (LQAL), 12.5 (MQAL) and 40 (HQAL) nM were< 6.1% for all THM for HQAL,< 4.4% at
MQAL (with the exception of rT3AM, T3AM and T4AM which were below 19.4%) and< 9.1%
at LQAL (with the exception of 3-T1, 3’-T1 and T0AM, which were< 14%). 3-Day inter-batch
accuracy for all QQALs (Table 5) were between 92.6–118.7% for all TN and TAM, with the
exception of T0AM, T4AM, T0Ac and T1Ac for LQAL which was<LLOQ for these compounds.
Intra-batch accuracies for all QQAL were in the range 88.7–108.8% (Table 6). The necessity for
using weighted linear regression for calibration curves that span a large concentration range was
evidenced by comparison of the mean accuracy value obtained at the LQAL (0.1 nM) concentra-
tion for PCCL3 cells with or without 1/x weighting across a range of TN/TAM (14 compounds)
for a single day. The mean % error using 1/x weighted calibration curves was 12%, whereas for
non-weighted curves the mean % error was 233%.
Table 3. Inter-day (n = 8) accuracy and precision for TH and TAM spiked lysed Hep G2 cell extracts in 24-well plates.






















T0 - - - 12.4 4.2 99 40.6 5.7 102
3-T1 0.10 9.9 104 12.5 8.3 100 41.1 5.7 103
3’-T1 0.11 8.7 107 12.6 5.9 100 41.1 7.1 103
3,5-T2 <LLOQ 12.6 7.2 101 41.9 6.8 105
3,3’-T2 0.11 [0.11] 8.7 [14.2] 109 [114] 12.6 [13.2] 6.6 [7.2] 100 [106] 41.5 [41.5] 6.9 [6.6] 104 [104]
3’,5’-T2 0.11 10.8 106 12.6 5.6 101 40.8 5.5 102
T3 0.11 [0.09] 9.3 [17.8] 105 [94] 12.4 [11.8] 8.3 [8.7] 99 [95] 42.8 [39.4] 7. [6.0] 107 [99]
rT3 0.10 7.5 104 12.3 8.2 98 41.0 6.9 102
T4 0.09 [0.10] 13.5 [8.1] 108 [103] 9.8 [12.1] 8.3 [6.1] 98 [96] 35.0 [39.4] 7.1 [5.0] 109 [98]
T0AM <LLOQ 12.8 5.7 102 41.6 6.5 104
3-T1AM 0.11 12.0 107 12.5 6.4 100 41.3 5.7 103
3,5-T2AM 0.10 6.1 103 12.0 5.8 96 41.3 5.8 103
T3AM 0.10 10.1 100 12.3 8.6 98 41.0 8.4 102
rT3AM 0.10 11.4 104 12.1 11.1 97 41.2 8.8 103
T4AM <LLOQ 11.6 12.5 92 40.1 11.0 100
CV [%]: Percentage coefficient of variation. LQAL: low concentration spiked quality-control sample. MQAL: medium concentration spiked quality-control
sample. HQAL: high concentration spiked quality-control sample. Values in parentheses were obtained by spiking samples with externally purchased TH
standard solutions (see experimental section); all other values were from internally prepared TH standard solutions. Lysed cell extracts contained ca. 0.060
nM T0 making quantification at 0.1 nM unreliable.
*All spiked concentrations for internally prepared TH standard solutions as labelled except: T4 LQAL (0.08 nM), MQAL (10 nM), HQAL (32 nM).
https://doi.org/10.1371/journal.pone.0183482.t003
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Recoveries, matrix effects and process efficiencies as analysed in two
cell lines
Recoveries, process efficiencies and matrix effects determined for extracted Hep G2 cell lysates
in 24-well plate format are displayed in Table 7. The recoveries for all TN, TAM and IS across
Table 4. Intra-day (n = 8) accuracy and precision for TH and TAM spiked lysed Hep G2 cell extracts in 24-well plates.
LQAL 0.10 nM MQAL 12.5 nM HQAL 40.0 nM
Compound Mean conc. [nM] CV
[%]
Accuracy [%] Mean conc. [nM] CV
[%]
Accuracy [%] Mean conc. [nM] CV
[%]
Accuracy [%]
T0 - - - 12.1 6.9 97 38.9 6.4 97
3-T1 0.10 12.6 104 12.6 5.7 101 40.4 5.5 101
3’-T1 0.09 15.0 92 12.1 6.3 97 40.0 6.6 100
3,5-T2 <LLOQ 12.5 5.8 100 40.0 5.4 100
3,3’-T2 0.10 8.5 99 12.3 5.0 99 39.5 4.8 99
3’,5’-T2 0.10 11.3 95 12.3 5.3 98 40.2 5.9 100
T3 0.10 10.2 104 12.2 5.1 98 38.7 7.6 97
rT3 0.12 11.9 116 11.5 3.1 92 38.2 8.0 96
T4 0.11 12.8 108 12.0 4.5 96 39.9 5.1 100
T0AM <LLOQ 12.2 5.1 98 38.7 7.6 97
3-T1AM 0.11 9.6 108 12.5 5.4 100 40.1 6.1 100
3,5-T2AM 0.12 6.3 120 12.2 6.1 97 40.7 5.1 102
T3AM 0.12 11.2 116 11.9 6.5 95 39.6 7.3 99
rT3AM 0.11 9.7 110 11.9 5.7 95 38.9 7.8 97
T4AM <LLOQ 12.9 4.3 103 38.0 7.6 95
Lysed cell extracts contained ca. 0.10 nM T0 making quantification at 0.10 nM unreliable.
https://doi.org/10.1371/journal.pone.0183482.t004
Table 5. Inter-day (n = 3) accuracy and precision for TH and TAM spiked lysed PCCL3 cell extracts in 6 well plates.


















T0 0.11 14.8 111 1.1 5.0 107 2.7 3.6 107
3-T1 0.11 9.6 112 1.1 1.9 105 2.7 1.5 107
3’-T1 0.11 7.0 106 1.0 1.4 104 2.6 1.6 105
3,5-T2 0.10 5.3 103 1.1 1.9 111 2.8 1.5 113
3,3-’T2 0.11 10.4 106 1.0 2.3 104 2.6 1.6 106
3’,5-’T2 0.11 10.5 106 1.0 4.9 104 2.7 5.0 108
T3 0.10 1.7 96 1.0 2.6 100 2.6 2.6 106
rT3 0.11 10.1 107 1.0 1.8 100 2.6 1.6 104
T4 0.11 10.4 108 1.0 3.2 100 2.6 2.0 104
T0AM <LLOQ 1.0 7.9 101 2.6 7.2 106
3-T1AM 0.11 8.1 111 1.0 1.9 105 2.7 1.6 109
3,5-T2AM 0.11 13.1 110 1.0 3.1 102 2.7 4.0 108
T3AM 0.12 21.8 119 1.0 9.1 95 2.6 9.1 104
rT3AM 0.11 23.1 107 0.9 13.2 93 2.6 13.8 102
T4AM <LLOQ 0.9 14.2 87 2.4 16.4 95
T0Ac <LLOQ 0.9 5.9 90 2.7 2.5 107
3-T1Ac <LLOQ 1.0 1.8 101 2.5 1.6 100
https://doi.org/10.1371/journal.pone.0183482.t005
LCMSMS method for PCCL3 thyrocytes
PLOS ONE | https://doi.org/10.1371/journal.pone.0183482 August 24, 2017 10 / 19
the range of QQALs (0.1 to 40 nM) were between 73–93%, the process efficiencies between
51–95%, and the matrix effects between 70–106%.
The same QA parameters were determined at a single concentration (1 nM) for extracted
PCCL3 cell lysates in 6-well plate format. Recoveries for all TN, TAM and TAc, including IS
varied from 75–101%, with % CV that varied between 2 and 17%. Process efficiencies were in
the range 58–89% with % CV from 1–17%; matrix effects ranged from 77–98% with % CV
between 1 and 14%. This data is displayed in Table 8.
Application
Identification of TN, TAM and TAc metabolites generated by PCCL3 cells. Identifica-
tion of THM in extracts of lysed PCCL3 cells and supernatants was confirmed or rejected by
both Rt and MRMqc as follows: T0: confirmed (Rt expected: 4.13, found: 4.10 min; MRMqc
within -4/+7% and -5/+14% of expected values in cell lysates and supernatants respectively);
T0AM: confirmed (Rt expected: 4.51, found: 4.51 min; MRMqc within -9/+4% and -14/+12%
of expected values in cell lysates and supernatants respectively). 3-T1Ac: confirmed in cell
lysates (Rt expected: 5.14, found: 5.13 min; MRMqc within -14/+16% of expected values);
confirmed only in cell supernatants with > 10 min incubation time (MRMqc -11/+15% of
expected values, for incubation times < 10 min the MRMqc exceeded +/- 20%). T0Ac: uncon-
firmed in cell lysates (Rt expected: 4.71, found: 4.73 min; MRMqc irreproducible and in many
cases > ±20% of expected value); confirmed in supernatants with > 10 min incubation time
(MRMqc -18/+3% of expected values)).
Method application to cell extracts and supernatants of rat thyrocytes after incubation
with mono-iodinated thyroid hormone metabolites. PCCL3 thyrocytes were incubated
with 500 nM of mono-iodinated representatives of the TAM, the TN and the TAc family for 5,
10 and 30 min. After incubation with 3-T1AM the un-metabolised parent substance was























T0 0.10 8.6 103 12.7 3.8 102 39.8 1.4 99
3T1 0.10 12.6 99 12.5 3.2 100 39.3 2.2 98
3’T1 0.09 12.7 94 12.8 2.8 103 40.1 1.1 100
3,5T2 0.10 5.3 100 12.9 2.4 103 39.3 2.2 98
3,3’T2 0.10 9.1 98 12.8 1.2 102 40.5 1.3 101
3’,5’-T2 0.11 6.6 108 12.6 2.4 101 39.9 1.9 100
T3 0.11 8.6 106 12.7 1.9 102 40.4 1.8 101
rT3 0.11 7.0 106 12.2 1.5 97 38.7 3.6 97
T4 0.10 4.5 103 12.6 1.6 101 39.9 1.6 100
T0AM 0.09 14.0 89 12.5 1.2 100 39.0 1.7 98
3T1AM 0.10 5.6 95 12.4 0.8 99 39.9 1.0 100
3,5T2AM 0.09 7.9 94 12.1 3.2 97 39.5 1.5 99
T3AM 0.10 8.8 104 11.1 17.0 89 39.4 3.2 98
rT3AM 0.10 6.3 101 11.1 18.8 89 38.4 4.2 96
T4AM <LLOQ 11.4 19.4 91 36.9 6.1 92
T0Ac <LLOQ 12.6 2.5 101 39.3 3.5 98
T1Ac <LLOQ 13.6 4.4 109 40.2 3.7 101
https://doi.org/10.1371/journal.pone.0183482.t006
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detectable in cell lysates with a clear increase in concentration over time (Fig 4A) indicating its
cellular uptake and intracellular accumulation. The extracellular concentration of 3-T1AM
remained almost constant over the course of 30 min (Fig 4C). The de-iodination product
T0AM and the de-amination product 3-T1Ac were detected in all cell extract samples (Fig 4A),
and were below LLOD in DMSO treated negative controls and in the parent stock solution.
These metabolites accumulated in the supernatants as evidenced (Fig 4C) by their increase in
concentration over time. 3-T1 was detectable in cell lysates after incubation, indicating cellular
uptake or binding of the parent substance (Fig 4B). Compared to 3-T1AM incubation, binding
or uptake of 3-T1 occurred to a substantially lesser extent. Furthermore, in contrast to
3-T1AM, no clear increase in 3-T1 concentration was observed with incubation time in cell
lysates. The T1 concentration in supernatants remained almost constant (Fig 4D).
The de-iodination product T0 was detected at low concentrations in all lysates after incuba-
tion with 3-T1 and in low but moderately increasing concentration in cell supernatants (Fig
4D), but not in DMSO controls or the 3-T1 stock solution. After incubation with 3-T1Ac, only
small amounts of the parent substance were detectable in cell lysates for each time point (high-
est concentration approximately 5 nM, data not shown), the bulk of the 3-T1Ac remained
unchanged in the cell supernatant (data not shown). As mentioned above, the putative de-
iodination product T0Ac was detected in cell lysates, but (even after 30 min incubation time)
at concentrations close to the limit of quantification making the confirmation of its identity
irreproducible. However, T0Ac was detected in supernatants after 10 and 30 min incubation at
mean concentrations of 5.6 and 10 nM respectively (data not shown).
Table 7. Inter-day (n = 8) process efficiency, matrix effect and recovery for TH and TAM spiked lysed Hep G2 cell extracts in 24-well plates.





















69 ± 12 84 ± 11 82 ± 10 69 ± 10 82 ± 9 81 ± 13 71 ± 10 86 ± 6 83 ± 13
13C6-3,3’T2 73 ± 8 87 ± 8 85 ± 8 74 ± 8 83 ± 5 85 ± 11 75 ± 9 87 ± 6 86 ± 11
13C6-T3 78 ± 8 91 ± 7 86 ± 8 80 ± 8 88 ± 5 89 ± 11 78 ± 10 88 ± 8 88 ± 12
13C6-rT3 67 ± 10 84 ± 11 80 ± 7 69 ± 8 79 ± 8 85 ± 10 70 ± 10 84 ± 8 84 ± 12
13C6-T4 67 ± 13 84 ± 13 80 ± 10 69 ± 11 80 ± 10 84 ± 11 68 ± 10 81 ± 10 85 ± 12
T0 148 ± 17 170 ± 15 87 ± 9 71 ± 8 91 ± 7 76 ± 12 72 ± 11 92 ± 6 78 ± 13
3-T1 78 ± 10 85 ± 8 91 ± 8 74 ± 10 88 ± 8 83 ± 13 75 ± 10 90 ± 7 84 ± 11
3’-T1 74 ± 9 84 ± 12 88 ± 10 70 ± 9 84 ± 7 81 ± 10 73 ± 10 87 ± 7 84 ± 13
3,5-T2 <LLOQ <LLOQ <LLOQ 81 ± 10 96 ± 8 83 ± 12 80 ± 11 94 ± 6 86 ± 10
3,3’-T2 75 ± 9 82 ± 10 92 ± 10 73 ± 9 87 ± 6 84 ± 10 76 ± 13 88 ± 6 86 ± 11
3’,5-’T2 70 ± 13 80 ± 13 88 ± 11 67 ± 9 83 ± 9 81 ± 11 71 ± 10 86 ± 7 82 ± 11
T3 81 ± 13 89 ± 10 91 ± 10 72 ± 11 87 ± 8 81 ± 12 75 ± 11 90 ± 7 84 ± 11
rT3 75 ± 10 86 ± 11 88 ± 10 68 ± 8 85 ± 7 83 ± 10 71 ± 10 87 ± 6 82 ± 11
T4 72 ± 20 83 ± 18 86 ± 12 64 ± 15 83 ± 13 79 ± 10 68 ± 15 86 ± 9 79 ± 12
T0AM <LLOQ <LLOQ <LLOQ 74 ± 13 87 ± 9 83 ± 13 77 ± 13 90 ± 7 84 ± 12
3-T1AM 75 ± 13 87 ± 15 87 ± 14 69 ± 11 87 ± 8 78 ± 13 72 ± 12 90 ± 5 80 ± 13
3,5-T2AM 71 ± 13 84 ± 12 85 ± 14 64 ± 14 85 ± 11 74 ± 12 67 ± 14 86 ± 8 78 ± 15
T3AM 64 ± 26 77 ± 33 85 ± 19 61 ± 15 79 ± 16 80 ± 11 66 ± 13 84 ± 9 78 ± 16
rT3AM 63 ± 14 80 ± 14 79 ± 19 59 ± 15 79 ± 11 79 ± 11 62 ± 16 81 ± 8 76 ± 18
T4AM <LLOQ <LLOQ <LLOQ 51 ± 21 70 ± 11 79 ± 10 60 ± 21 74 ± 15 73 ± 24
Values were obtained by spiking samples with in-house prepared TH standard solutions. Lysed cell extracts contained ca. 0.10 nM T0, thus results at 0.10
nM are skewed.
https://doi.org/10.1371/journal.pone.0183482.t007
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Table 9 shows mass balance data for the above incubation experiments. For all three incu-
bation substances over all time points, mass balance totals were in the range of 66–84%. For
3-T1 incubation, 4–5% of the parent substance was accounted for in the extracts of cell lysates,
62–63% was evident in the supernatant. The de-iodinated metabolite T0 accounted for only
0.2% of the total mass balance in cell lysates after 30 min and in marginally higher amounts
(0.4%) in supernatants. The percentage balance of 3-T1AM remained constant at ca. 40% in
supernatants over the entire course of 3-T1AM incubation, but increased from 29% after 5
min to 41% after 30 min in cell lysates. The percentage balance of the de-iodination metabolite
T0AM, which was present at low concentrations, increased in supernatants from 0.1 (10 min)
to 0.8% (30min), but stayed constant at 0.2–0.4% in cell lysates. The de-amination product
3-T1Ac constituted only 0.1–0.2% of the total in cell lysates for all time points and was detected
only after 30 min in supernatants at 1.2%. Finally, T1Ac was not substantially accumulated by
PCCL3 cells and remained between 77–81% of the total accountable pmol amount in superna-
tants. The % pmol of the de-iodinated product T0Ac increased from 1.1 to 1.9% of total pmol
from 10 to 30 min.
Discussion
LC-MS/MS method validation
We applied our previously published LC-MS/MS method [12], with minor modifications, to
the analysis of Hep G2 cell lysate extracts. In brief, the method features a 10 min analysis time
Table 8. Inter-day (n = 3) process efficiency, matrix effect and recovery for TH and TAM spiked lysed PCCL3 cell extracts in 6 well plates.
Compound QQAL 1 nM (n = 3)
PE ± SD ME ± SD RE ± SD
2H4-T0Ac 89 ± 12 89 ± 8 100 ± 17
2H4-T1Ac 80 ± 7 98 ± 7 82 ± 6
2H4-3-T1AM 76 ± 6 90 ± 7 85 ± 7
13C6-3,3’T2 77 ± 5 94 ± 7 82 ± 4
13C6-T3 80 ± 6 93 ± 3 85 ± 7
13C6-rT3 66 ± 7 88 ± 6 75 ± 6
13C6-T4 72 ± 10 92 ± 4 79 ± 11
T0 72 ± 3 87 ± 2 82 ± 3
3-T1 81 ± 5 90 ± 3 90 ± 3
3’-T1 78 ± 6 93 ± 3 84 ± 4
3,5-T2 88 ± 9 96 ± 4 91 ± 6
3,3-T2 79 ± 4 93 ± 3 85 ± 2
3’,5’-T2 75 ± 6 94 ± 1 80 ± 7
T3 74 ± 2 91 ± 2 81 ± 4
rT3 70 ± 5 89 ± 4 79 ± 5
T4 68 ± 10 94 ± 3 78 ± 3
T0AM 84 ± 8 97 ± 2 87 ± 8
3-T1AM 79 ± 4 90 ± 1 88 ± 5
3,5-T2AM 73 ± 5 88 ± 3 83 ± 3
T3AM 69 ± 1 82 ± 11 84 ± 9
rT3AM 64 ± 4 81 ± 10 80 ± 10
T4AM 58 ± 10 79 ± 13 80 ± 14
T0Ac 77 ± 17 77 ± 14 101 ± 12
3-T1Ac 82 ± 8 96 ± 13 86 ± 5
https://doi.org/10.1371/journal.pone.0183482.t008
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Fig 4. Application of the LC-MS/MS method to extracts of PCCL3 rat thyrocytes. THM in extracts of PCCL3 (A, B) cell and
supernatants (C, D) after incubation with 500 nM 3-T1AM (A, C) or 3-T1 (B, D) in Krebs-Ringer buffer as measured by LC-MS/MS. Bars
represent means of 3 independent experiments carried out on different days +/- SEM.
https://doi.org/10.1371/journal.pone.0183482.g004
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for the 9 TN and 6 TAM in positive ion mode and complete baseline chromatographic separa-
tion for the three isobaric T2 isomers (due to identical precursor and product ion selections,
these isomers must be separated chromatographically for individual quantification). Wherever
possible, structurally identical, stable isotopically labelled IS for quantification were used for
each analyte to enhance the accuracy of the method [20]. In cases where no identical IS was
commercially available, an IS with the closest structural similarity was applied.
We also adapted this method for the analysis of PCCL3 cell lysate extracts by using positive/
negative electrospray ionisation switching to further incorporate negative ion electrospray
MRM transitions for T0Ac and T1Ac and their respective (
2H4-T0Ac and
2H4-T1Ac) IS.
Across the range of QQAL concentrations and cell lines PE were ca. 17–24% lower than for
those measured in cell culture media [12]. For the most part RE were not substantially worse
for cell lysates extracts (4–13% less across both cell lines and QQAL concentrations) compared
to culture media extracts. ME for Hep G2 in contrast to cell culture media tended to decrease
substantially with increasing QQAL concentration and were 22% higher for the LQAL (0.10
nM) than for the culture media LQAL (0.75 nM), 15% higher at MQAL (10 vs 12.5 nM) but
comparable at HQAL (40 vs 80 nM) concentrations. These results would seem to be consistent
with greater LC-MS/MS ion suppression effects caused by the dirtier cell lysate matrix. The
marginally lower RE could arise from hormone adhesion to cell culture plates.
Application of the LC-MS/MS method to extracts of PCCL3 rat
thyrocytes
We successfully applied the described LC-MS/MS method to investigate THM in PCCL3 thyr-
ocytes after incubation with 3-T1AM, 3-T1 and 3-T1Ac. The data obtained demonstrate that
3-T1AM is de-iodinated to T0AM and de-aminated to 3-T1Ac, while 3-T1 is de-iodinated to T0
by PCCL3 cells. This indicates 3-T1AM and 3-T1 uptake and intracellular metabolism by the
cell line and confirms tyrosyl ring de-iodination activity as well as activity of an amino oxidase
in PCCL3 cells as previously suggested [21]. Thus, the interpretation of 3-T1AM effects on the
hypothalamus-pituitary-thyroid (HPT) axis in mice treated with this biogenic amine [21] and
actions observed in thyrocyte cell culture, should consider the possibility of direct biological
action of its metabolites. Our findings of in vitro 3-T1AM de-iodination to T0AM and de-ami-
nation to 3-T1Ac are in line with previous data obtained in different cell lines by others ([22],
[23]). However, in the related thyrocyte model FRTL-5 the catabolite T0Ac was detected addi-
tionally. In this study, virtually all of the produced T0Ac was detected in the incubation
medium [22].
PCCL3 cells accumulate T1 and T1AM and T0AM, but not T1Ac or T0Ac. We observed a
time-dependent increase in recovery, probably due to cellular accumulation of TH/THM,
which may indicate some adhesion of TH/THM to cell culture plastic in the absence of TH/
THM binding proteins in incubation medium. Cells de-iodinate T1 to T0, which mainly accu-
mulates in the supernatant, suggesting uptake of T1 and export of T0. Cells also accumulate
T1AM and de-iodinate it to T0AM, the majority of which is again exported; T1Ac also appears
in supernatants, but only at later time points. In contrast, T1Ac is not accumulated by PCCL3
cells, but rather exported over time and also de-iodinated to T0Ac, which appears in the
supernatant.
Generally, only limited metabolism of these TH/THM occurs in PCCL3 over the first 30
min. Less than 1% of T1 is de-iodinated to T0, around 5% of 3T1AM is metabolized to T0AM
and 3T1Ac and less than 2.5% of 3T1Ac is de-iodinated to T0Ac when offered as the sole sub-
strate to PCCl3 cells. Recoveries of TH and THM carrying only one or no iodine atom ranges
between 66 and 84% (values were not corrected for any losses in the sample extraction process,
LCMSMS method for PCCL3 thyrocytes
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the relative recoveries of the method would account for the fact that mass balances do not total
100%). These recoveries are comparable to those of the classical TH, T4 and T3, in this and
other cell lines during uptake and metabolism experiments ([12], [13]). Interestingly, 3T1Ac
exhibits the highest recovery and lowest accumulation in cell extracts, which might indicate
that both its precursors 3T1 and 3T1AM are more avidly bound by cells, and metabolized intra-
cellularly. Some (irreversible) binding of both substrates to cellular targets cannot be excluded.
However, the time dependent increase in recovery may also indicate that initially these TH/
THM compounds may absorb to cell culture plastic surfaces and thus escape complete extrac-
tion by our currently employed procedure.
The observation of significant amounts of iodine-free T0 in extracts of HepG2 cells cannot
yet be explained satisfactorily. As blank solutions, reagents and standards used during the pre-
analytical workup and LC-MS/MS analysis do not contain measurable amounts of T0, we sup-
pose that it might be carried over from T0-containing FCS, which is required for the initial
steps of cell culture. Alternatively, HepG2 cells may transiently accumulate T0 from serum in
the culture medium or eventually generate it from accumulated TH and THM. Up to now, fate
and metabolism of T0 have rarely been studied in cell culture experiments, whilst formation
and renal secretion into urine has been reported using various methods ([24], [25], [26]). In
humans, T0 has been described and quantified by immunoassays and mass spectrometry at
low nanomolar concentrations in urine, indicating that not all iodothyronines are fully de-
iodinated to recover their content of the essential trace element iodine for its recycling by the
thyroid gland.
In conclusion, we have shown that TH and THM can be quantified precisely and accurately
to a LLOQ of 0.031–0.125 nM for TN (except for T0 in HepG2 cells, which contained baseline
concentrations) and 0.031–05 nM for TAM in Hep G2 and PCCL3 cell lysate extracts. ME for
all TN, TAM and TAc were acceptable for both cell lines (>70%) and RE were>73% in all
cases. For both cell lines, PE, an indication of the overall efficacy of pre-analytic extraction and
LC-MS/MS measurement for TH and THM in the sample matrix, were substantially less than
for culture media [12]. This is due to increased ME from the cell sample matrix. PE were how-
ever reproducible for all TN, TAM and TAc in PCCL3 cells (10% CV or better) with the excep-
tion of T0Ac (17% CV) and better than 20% for all TN and TAM in Hep G2 cell lysate extracts
with the exception of T3AM and T4AM (26 and 21% CV respectively). We therefore expect the
reported methods to find wide applicability for the quantitative analysis of TH and THM in
cell lysates.
By applying our positive/negative electrospray switched tandem LC-MS/MS method to the
analysis of cell lysate and supernatant extracts recovered from the 30 min incubation of mono-
iodinated TN, TAM and TAc with PCCL3 rat thyrocytes, we were able to follow the progress
of limited de-iodination of T1, T1AM and T1Ac and the de-amination of T1AM to T1Ac.
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